Vaccines & Immunization
A boards-focused immunology lesson on vaccines: active vs passive immunity and the memory/secondary response, the major vaccine platforms (live, killed, subunit, conjugate, polysaccharide, toxoid, mRNA) with the T-independent-to-T-dependent conjugate principle, and clinical correlations of immunodeficiency, asplenia, complement deficiency, and pregnancy to vaccine choice.
Active vs Passive Immunity — Why Vaccines Work
Vaccination is active immunization: the host is exposed to a harmless form of an antigen and mounts its own adaptive response, generating memory B and T cells. The payoff is the secondary (anamnestic) response — on true exposure, memory B cells drive a faster, larger, higher-affinity, class-switched (IgG-predominant) antibody response, in contrast to the slow, low-titer, IgM-predominant primary response.
Passive immunization is the opposite: transfer of preformed antibody (maternal IgG across the placenta, secretory IgA in breast milk, IVIG, antitoxins, monoclonal antibodies). Onset is immediate but protection is short-lived (IgG t½ ≈ 3 weeks) and confers no memory.
Crucially, high-affinity, class-switched, memory responses require T-cell help: in the germinal center, CD4⁺ T follicular helper (Tfh) cells engage B cells via CD40L–CD40 plus cytokines (IL-21, IL-4), driving isotype switching, somatic hypermutation/affinity maturation, and memory. This is why a vaccine's molecular design (protein vs pure polysaccharide) dictates the quality of immunity.
- Active = host makes its own Ab + memory (slow onset, long-lasting). Passive = preformed Ab given (fast onset, ~weeks, no memory).
- Live attenuated vaccines elicit both humoral and cell-mediated (CD8⁺) immunity and are usually strongest/longest-lasting — but are contraindicated in pregnancy and significant immunodeficiency (disseminated infection / reversion to virulence).
- Inactivated (killed) vaccines elicit mainly humoral immunity, need boosters, and are safe in immunocompromised/pregnant hosts (no live organism).
- Pure polysaccharide antigens are T-independent → mostly IgM, poor memory, ineffective in children <2 yr. Conjugation to a protein carrier makes them T-dependent → IgG class-switch, memory, works in infants.
- Toxoid vaccines (tetanus, diphtheria) generate antitoxin IgG against the exotoxin, not against colonization.
- Polio has two forms: Sabin = live-attenuated oral (OPV, can revert → vaccine-associated paralytic polio); Salk = killed injected (IPV). Memory hook: Sal-K = Killed.
- Two live (injectable/intranasal) vaccines not given the same day should be separated by ≥4 weeks.
- Adjuvants (e.g., aluminum salts/alum) boost immunogenicity of killed/subunit vaccines by supplying the innate 'danger' signal that activates APCs.
Vaccine Types — Mechanism, Examples, Caveats
| Type | Mechanism / immunity elicited | Key examples | Boards caveats |
|---|---|---|---|
| Live attenuated | Replicating but weakened organism → strong humoral + cell-mediated (CD8⁺); often lifelong | MMR, varicella, rotavirus, intranasal influenza (LAIV), oral polio (Sabin), yellow fever, BCG, oral typhoid, smallpox, adenovirus | Contraindicated in pregnancy & immunodeficiency; can revert to virulence; needs cold chain |
| Killed / inactivated | Non-replicating whole pathogen → humoral only, weaker | Rabies, influenza (IM shot), polio (Salk/IPV), hepatitis A | Needs boosters; safe in immunocompromised/pregnancy |
| Subunit / recombinant | Purified antigen/protein → humoral | HBV (HBsAg), HPV (L1 virus-like particle), acellular pertussis, recombinant zoster (Shingrix), MenB | No live organism; usually adjuvanted/boosted |
| Conjugate | Capsular polysaccharide + protein carrier → T-dependent IgG + memory; works <2 yr | Hib, PCV13/15/20 (pneumococcus), MenACWY | Overcomes weak T-independent pure-polysaccharide response |
| Polysaccharide (pure) | Capsular sugar alone → T-independent, IgM, poor memory | PPSV23 (pneumococcus) | Ineffective <2 yr; no durable memory |
| Toxoid | Inactivated exotoxin → antitoxin IgG | Tetanus, diphtheria | Protects vs toxin, not colonization; boosters ~q10y |
| mRNA | LNP-delivered mRNA → host cells express antigen → humoral + cellular | COVID-19 (spike) | Ultra-cold storage; not live, no genome integration |
- Encapsulated bacteria (S. pneumoniae, H. influenzae type b, N. meningitidis) resist phagocytosis behind a polysaccharide capsule; protective immunity depends on anti-capsular opsonizing IgG.
- Pure polysaccharide capsule is a T-independent type 2 antigen — it cross-links B-cell receptors → IgM, minimal class-switch, no memory, and fails in children <2 yr (immature marginal-zone B cells).
- A conjugate vaccine covalently links the polysaccharide to a carrier protein (tetanus/diphtheria toxoid, CRM197). The polysaccharide-specific B cell internalizes the whole conjugate, processes the protein, and presents its peptides on MHC II → recruits carrier-specific Tfh help via CD40L–CD40 + IL-21/IL-4 → class-switch to IgG, affinity maturation, memory B cells, and efficacy in infants.
- Practical result: infants receive Hib and PCV (conjugate); PPSV23 (pure polysaccharide) is reserved for ≥2 yr / high-risk adults.
- Adjuvants (alum) supply the innate 'danger' signal that killed/subunit antigens lack, activating APCs to license a robust adaptive response.
- Live vaccine in cellular immunodeficiency — An infant with SCID develops disseminated disease after the live rotavirus vaccine, disseminated BCG ('BCGosis') after BCG, or vaccine-associated paralytic poliomyelitis after OPV. → Live vaccines are contraindicated in severe cellular immunodeficiency.
- Asplenia / functional asplenia — A child with sickle cell disease (autosplenectomy) or a post-splenectomy patient is at risk for overwhelming sepsis from encapsulated organisms (S. pneumoniae, H. influenzae b, N. meningitidis — 'SHiN'). → Ensure PCV + PPSV23, Hib, and meningococcal (MenACWY + MenB); the spleen drives both anti-polysaccharide IgM and clearance of opsonized encapsulated bugs.
- Terminal complement deficiency (C5–C9 / MAC) — Recurrent Neisseria infections. → Meningococcal vaccination is essential (also mandated for patients on eculizumab, an anti-C5 mAb, which blocks MAC formation).
- Pregnancy — Live vaccines (MMR, varicella, LAIV) are contraindicated; give inactivated influenza and Tdap each pregnancy (~27–36 wk) so maternal IgG passively protects the newborn from pertussis.
- HIV nuance (Step 2 CK) — MMR/varicella may be given if not severely immunosuppressed (CD4 ≥ 200 cells/µL or ≥15%); avoid if CD4 < 200.
Host / Situation → Vaccine Approach
| Host / situation | Immunologic issue | Vaccine implication |
|---|---|---|
| Pregnancy | Live virus risk to fetus | No live (MMR, varicella, LAIV); give Tdap + inactivated flu |
| SCID / severe cellular immunodeficiency | Cannot contain a replicating organism | No live vaccines; watch disseminated BCG / rotavirus / OPV |
| Asplenia / sickle cell | ↓ clearance of encapsulated bugs, ↓ anti-polysaccharide IgM | Pneumococcal + Hib + meningococcal (encapsulated coverage) |
| Terminal complement (C5–C9) deficiency / eculizumab | Cannot form MAC against Neisseria | Meningococcal (MenACWY + MenB) |
| HIV, CD4 ≥ 200 | Partial cellular function | MMR/varicella allowed; avoid if CD4 < 200 |
| Newborn of HBsAg⁺ mother | No time to mount active immunity | HBV vaccine + HBIG (active + passive) at birth |
| Severe egg allergy | Some vaccines are egg-grown | Caution/contraindication with yellow fever; current flu vaccines are tolerated (egg allergy no longer a barrier) |
Passive (preformed-antibody) post-exposure — First Aid "To Be Healed Very Rapidly": Tetanus toxin · Botulinum toxin · HBV · Varicella (VZIG) · Rabies. These are the exposures where you give immune globulin (± vaccine) because there's no time for an active response.
Polio — "Sal-K = Killed": Salk = killed, injected (IPV); Sabin = live-attenuated oral (OPV, can revert → VAPP).
Encapsulated organisms to vaccinate against (asplenia, terminal complement/eculizumab) — "SHiN": S. pneumoniae · H. influenzae type b · N. meningitidis.
Live vs killed strategy: there is no single reliable sentence mnemonic for the full live-attenuated list, so memorize the short killed/inactivated list (rabies, IPV, hepatitis A, injected influenza) plus the subunit/toxoid vaccines, and treat the remaining replicating vaccines (MMR, varicella, rotavirus, intranasal LAIV, oral polio/Sabin, yellow fever, BCG, oral typhoid, smallpox, adenovirus) as the live group.
Passive Immunization & Post-Exposure Prophylaxis
Passive immunization delivers preformed antibody for immediate but temporary protection — used when there's no time for an active response or when the host cannot make antibody.
- Maternal transfer: IgG crosses the placenta (protects the neonate ~6 months); secretory IgA in breast milk protects mucosal surfaces.
- IVIG / replacement: for antibody deficiencies (X-linked agammaglobulinemia, CVID).
- Antitoxins / antivenom: preformed antibody neutralizes tetanus, botulinum, and diphtheria toxins, and snake venom.
- Monoclonal antibodies: e.g., RSV prophylaxis (palivizumab / nirsevimab) in high-risk infants.
- Combined active + passive for high-risk exposures — give vaccine and immune globulin together: Hepatitis B (HBV vaccine + HBIG), Rabies (vaccine + RIG), and a tetanus-prone wound in an unimmunized patient (Tdap + TIG).
- Caveat: recently administered antibody (IVIG, blood products) can blunt the take of live vaccines — defer MMR/varicella for the appropriate interval after immune globulin.
Practice Immunology now
Board-style questions, spaced-repetition flashcards, and a Socratic AI tutor — free to start.